First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a ...
Moderna, Inc., a pioneer and leader in the field of mRNA medicine, and Merck, known as MSD outside of the United States and Canada, announced detailed results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results